Precigen (PGEN) Surged Following the Early Approval of Papziemos

1 hour ago 1

Soumya Eswaran

Thu, March 5, 2026 astatine 7:40 AM CST 3 min read

Patient Capital Management, a worth investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. In Q4 2025, Patient Opportunity Equity Strategy returned 5.99% nett of fees, compared to its unmanaged benchmark, the S&P 500 Index, which returned 2.65%. Through a three-factor show attribution model, the portfolio's outperformance was attributed to allocation, selection, and enactment effects. The marketplace ended a beardown twelvemonth with 17.9% returns, marking the seventh-best three-year play successful marketplace history. 2025 was a twelvemonth of AI, extending the benefits to hardware, energy, and constituent suppliers crossed the ecosystem. Seven stocks accounted for implicit fractional of the S&P 500’s returns, posing difficulties for progressive managers. Nevertheless, the strategy performed well, outperforming the S&P 500 for the 3rd consecutive twelvemonth with a instrumentality of 26.1%. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, Patient Opportunity Equity Strategy highlighted Precigen, Inc. (NASDAQ:PGEN) arsenic 1 of its starring contributors. Precigen, Inc. (NASDAQ:PGEN) is simply a find and clinical-stage biopharmaceutical institution focusing connected processing cistron and compartment therapies successful areas of immuno-oncology, autoimmune disorders, and infectious diseases. On March 04, 2026, Precigen, Inc. (NASDAQ:PGEN) banal closed astatine $3.55 per share. One-month instrumentality of Precigen, Inc. (NASDAQ:PGEN) was -16.27%, and its shares gained 89.84% implicit the past 52 weeks. Precigen, Inc. (NASDAQ:PGEN) has a marketplace capitalization of $1.256 billion.

Patient Opportunity Equity Strategy stated the pursuing regarding Precigen, Inc. (NASDAQ:PGEN) successful its 4th fourth 2025 capitalist letter:

"Precigen, Inc. (NASDAQ:PGEN) continued to beryllium a apical contributor to the strategy pursuing the aboriginal support of Papziemos for the attraction of recurrent respiratory papillomatosis (RRP) successful aboriginal August. With this approval, Papziemos became the first-in people "off-the-shelf" immunotherapy for a diligent colonisation with nary different attraction options. As the institution moves rapidly to motorboat the drug, it inches person to self-funding allowing it to beforehand its different pipeline assets toward approval. The institution is led by Dr. Helen Sabzevari, who brings extended expertise successful immunotherapy-based therapeutics, having founded and served arsenic Chief Scientific Officer of Compass Therapeutics. She has driven singular objective advancement astatine Precigen implicit the past fewer years, and we expect her to use a akin playbook to their different pipeline assets successful Phase 2 and Phase 1/1b development. We inactive spot charismatic upside fixed aggregate blockbuster assets successful development."

Read Entire Article